InolitazonePPARgamma agonist CAS# 223132-37-4 |
- GW1929
Catalog No.:BCC1611
CAS No.:196808-24-9
- Balaglitazone
Catalog No.:BCC1395
CAS No.:199113-98-9
- Inolitazone dihydrochloride
Catalog No.:BCC1653
CAS No.:223132-38-5
- Aleglitazar
Catalog No.:BCC1337
CAS No.:475479-34-6
- L-165041
Catalog No.:BCC1687
CAS No.:79558-09-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 223132-37-4 | SDF | Download SDF |
| PubChem ID | 9832447 | Appearance | Powder |
| Formula | C27H26N4O4S | M.Wt | 502.58 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Efatutazone; CS-7017; RS5444 | ||
| Solubility | DMSO | ||
| Chemical Name | 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methylbenzimidazol-2-yl]methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | ||
| SMILES | CC1=CC(=CC(=C1N)C)OC2=CC3=C(C=C2)N=C(N3C)COC4=CC=C(C=C4)CC5C(=O)NC(=O)S5 | ||
| Standard InChIKey | JCYNMRJCUYVDBC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C27H26N4O4S/c1-15-10-20(11-16(2)25(15)28)35-19-8-9-21-22(13-19)31(3)24(29-21)14-34-18-6-4-17(5-7-18)12-23-26(32)30-27(33)36-23/h4-11,13,23H,12,14,28H2,1-3H3,(H,30,32,33) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Inolitazone a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.In Vitro:Inolitazone (RS5444) upregulates the cell cycle kinase inhibitor, p21 WAF1/CIP1. Silencing p21 WAF1/CIP1 rendered cells insensitive to Inolitazone. A 10 nM dose of Inolitazone activates PPARγ:RXRα-dependent transcription as demonstrated in a transient transfection assay utilizing a PPRE response element fused to a luciferase reporter gene (PPRE3-tk-luc). DRO cells are treated in culture with Inolitazone, Rosiglitazone, or Troglitazone at the indicated concentrations. DRO cells are transiently transfected with PPRE3-tk-luc to examine effective concentrations at which EC50 occurs. The EC50s are 1 nM (Inolitazone), 65 nM (Rosiglitazone) and 631 nM (Troglitazone). Similarly, the calculated inhibitory concentration at IC50 is 0.8 nM for Inolitazone, 75 nM for Rosiglitazone, and 1412 nM for Troglitazone. Inolitazone specifically activates PPARγ, but not PPARα or PPARδ. Exposure of 10 nM Inolitazone following transient transfection with the appropriate PPAR isoform (γ, α, or δ) and PPAR response element linked to a luciferase reporter in RIE rat small intestinal cell line, which does not express PPARs, yields increased luciferase activity only in the presence of PPARγ and PPRE3-tk-luc[1]. DRO cells are growth inhibited by 10 nM Inolitazone (RS5444) through a PPARγ-dependent mechanism[2].In Vivo:Inolitazone (RS5444) plus Paclitaxel demonstrate additive antiproliferative activity in cell culture and minimal ATC tumor growth. When Inolitazone is administered in the diet to athymic nude mice prior to DRO tumor cell implantation, tumor growth is inhibited in a dose responsive fashion. At the highest dose, 0.025% Inolitazone inhibits growth on day 32 by 94.4% as compared to that of control. In this treatment group, five of 10 animals do not develop demonstrable tumors. In the 0.0025% treatment group, tumor growth is inhibited by 62.3% compared to that of control on day 32 while the 0.00025% dose demonstrated no growth inhibitory activity as compared to control. Tumors is nest allowed to establish in the mouse and began 0.025% Inolitazone treatment of mice 1 week after DRO or ARO tumor cell implantation. Inolitazone treated animals demonstrate tumor growth inhibition of 68.9% in DRO tumors and 48.3% in ARO tumors as compared to that of their respective controls on day 35[1]. References: | |||||
Inolitazone Dilution Calculator
Inolitazone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9897 mL | 9.9487 mL | 19.8973 mL | 39.7947 mL | 49.7433 mL |
| 5 mM | 0.3979 mL | 1.9897 mL | 3.9795 mL | 7.9589 mL | 9.9487 mL |
| 10 mM | 0.199 mL | 0.9949 mL | 1.9897 mL | 3.9795 mL | 4.9743 mL |
| 50 mM | 0.0398 mL | 0.199 mL | 0.3979 mL | 0.7959 mL | 0.9949 mL |
| 100 mM | 0.0199 mL | 0.0995 mL | 0.199 mL | 0.3979 mL | 0.4974 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: IC50 Value: 0.8 nM [1] Inolitazone(RS5444) is a novel high-affinity PPARgamma agonist, which activates PPARgamma with an EC50 about 1/50th that of rosiglitazone and has no effect on RIE cells that do not express PPARgamma. in vitro: In vitro, the IC50 for growth inhibition is approximately 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three- to fourfold in nude mice. siRNA against PPARgamma and a pharmacological antagonist demonstrated that functional PPARgamma was required for growth inhibitory activity of RS5444. RS5444 upregulated the cell cycle kinase inhibitor, p21WAF1/CIP1 [1]. RS5444inhibited culture growth and caused irreversible G1 arrest, but did not induce apoptosis. In addition, RS5444 caused dramatic changes in cellular morphology which were associated with increased motility and diminished cellular adherence, but no increase in the ability of such cells to digest and invade Matrigel [2]. Treatment with RS5444 leads to the up-regulation of RhoB and subsequent activation of p21, and that silencing of RhoB by RNAi blocks the ability of RS5444 to induce p21 and to inhibit ATC cells proliferation [3]. in vivo: The median peak efatutazone blood level was 8.6 ng/mL for 0.15-mg dosing vs 22.0 ng/mL for 0.3-mg twice daily dosing [4]. Although efatutazone treatment did not reduce percentage of mice developing invasive cancer, it significantly reduced prevalence of noninvasive cancer and total number of cancers per mouse and increased prevalence of well-differentiated cancer subtypes not usually seen in this mouse model [5]. Clinical trial: CS-7017 in Combination with Carboplatin/Paclitaxel in Subjects with Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC). Phase 1b
- SEA0400
Catalog No.:BCC1941
CAS No.:223104-29-8
- Finasteride acetate
Catalog No.:BCC4204
CAS No.:222989-99-3
- Noladin ether
Catalog No.:BCC5756
CAS No.:222723-55-9
- SZL P1-41
Catalog No.:BCC8004
CAS No.:222716-34-9
- Chysin A
Catalog No.:BCN2020
CAS No.:22269-11-0
- ACBC
Catalog No.:BCC6584
CAS No.:22264-50-2
- Antidesmone
Catalog No.:BCN5058
CAS No.:222629-77-8
- Bromocriptine mesylate
Catalog No.:BCC6642
CAS No.:22260-51-1
- Tempol
Catalog No.:BCC4862
CAS No.:2226-96-2
- Adoprazine
Catalog No.:BCC1329
CAS No.:222551-17-9
- Loganic acid
Catalog No.:BCN5057
CAS No.:22255-40-9
- Lucidin 3-O-glucoside
Catalog No.:BCN8249
CAS No.:22255-29-4
- Inolitazone dihydrochloride
Catalog No.:BCC1653
CAS No.:223132-38-5
- Evodol
Catalog No.:BCN5059
CAS No.:22318-10-1
- Platycodigenin
Catalog No.:BCN3183
CAS No.:22327-82-8
- Methyl ferulate
Catalog No.:BCN4023
CAS No.:22329-76-6
- 9-Hydroxy-alpha-lapachone
Catalog No.:BCN5060
CAS No.:22333-58-0
- Grandiflorenic acid
Catalog No.:BCN4670
CAS No.:22338-67-6
- Grandifloric acid
Catalog No.:BCN4669
CAS No.:22338-69-8
- Polygalacic acid
Catalog No.:BCN5898
CAS No.:22338-71-2
- FG2216
Catalog No.:BCC6402
CAS No.:223387-75-5
- GLP-2 (human)
Catalog No.:BCC5891
CAS No.:223460-79-5
- ONO 4817
Catalog No.:BCC2375
CAS No.:223472-31-9
- YM 58483
Catalog No.:BCC7817
CAS No.:223499-30-7
